We connect science and compassion to reimagine mental health care.
Compass Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health.
We are studying investigational psilocybin treatment in treatment-resistant depression, post-traumatic stress disorder and anorexia nervosa.
Our stories
Everyone has a story about how mental illness has affected them or someone they know. Our people bring their stories, and a wide range of backgrounds and skills, to Compass.
Our research
Our research is driven by a commitment to find better ways to support and empower people living with mental illness.
News and views
Our collective understanding of mental illness is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology, and digital platforms.
-
Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment...
Read article
-
COMPASS Pathways Announces Third Quarter 2023 Financial Results and Business Highlights
Read article
-
Compass Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthca...
Read article